[A24-124] Ribociclib (breast cancer, adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Last updated 17.03.2025
Project no.:
A24-124
Commission:
Commission awarded on 17.12.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adjuvant treatment of patients with HR-positive, HER2-negative early breast cancer at high risk of recurrence
Result of dossier assessment:
- Premenopausal women: added benefit not proven
- Postmenopausal women: added benefit not proven
- Men: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-124
| Project no. | Title | Status |
|---|---|---|
| A20-22 | Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-21 | Ribociclib (breast cancer; combination with aromatase inhibitors) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-06 | Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-45 | Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |